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Abstract
Background: The “Put Prevention into Practice” campaign of the US Public Health Service (USPHS) was launched
with the dissemination of the Clinician’s Handbook of Preventive Services that recommended standards of clinical
care for various prevention activities, including preventive clinical strategies to reduce the risk of adverse drug
events. We explored whether nonprescribing clinicians such as chiropractors may contribute to advancing drug
safety initiatives by identifying potential adverse drug events in their chiropractic patients, and by bringing
suspected adverse drug events to the attention of the prescribing clinicians.
Methods: Mail survey of US chiropractors about their detection of potential adverse drug events in their
chiropractic patients.
Results: Over half of responding chiropractors (62%) reported having identified a suspected adverse drug event
occurring in one of their chiropractic patients. The severity of suspected drug-related events detected ranged from
mild to severe.
Conclusions: Chiropractors or other nonprescribing clinicians may be in a position to detect potential adverse
drug events in the community. These detection and reporting mechanisms should be standardized and policies
related to clinical case management of suspected adverse drug events occurring in their patients should be
developed.
Introduction
The “Put Prevention into Practice” campaign of the US
Public Health Service (USPHS) was launched in 1994 with
the dissemination of the Clinician’sH a n d b o o ko fP r e v e n -
tive Services that recommended standards of clinical care
for various prevention activities. We used the USPHS
Clinician’s Handbook of Preventive Services (1
st edition,
1994) as source material to identify a set of prevention
activities with potential relevance to chiropractic clinical
practice, such as counseling chiropractic patients about
physical activity, nutrition, or smoking cessation [1].
The first edition USPHS clinician’s handbook identi-
fied preventive clinical strategies to reduce the risk of
polypharmacy and the attendant risk of overmedication
and adverse effects, and outlined for clinicians the basics
of polypharmacy counseling and guidelines for simplify-
ing medication regimens [1]. Chiropractors without
prescriptive authority would not be directly responsible
for simplifying or otherwise altering the prescribed med-
ications regimens of their patients. The overwhelming
majority of chiropractors in the U.S. do not prescribe
drugs (aside from a small cadre of newly credentialed,
limited formulary “advanced practice chiropractors”)
[2,3]. However, nonprescribing clinicians such as chiro-
practors may also contribute to advancing drug safety
initiatives by identifying potential adverse drug events in
their chiropractic patients, and by bringing suspected
adverse drug events to the attention of the prescribing
clinicians.
Methods
We conducted a comprehensive multi-topic survey of US
chiropractors in 2002-03 to assess their attitudes and
behaviors on an encompassing range of various clinical
and professional dimensions. All survey questions had
been prevalidated by pilot-testing on key informants
identified through chiropractic leadership rosters of the
Congress of Chiropractic State Associations (COCSA),
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and the National Board of Chiropractic Examiners
(NBCE). Our study methods have been reported in
extensive detail elsewhere [4-6]. We drew our rando-
mized survey sampling frame (n = 5,931) from a master
list of all US state-board licensed DCs (N = 67,217), and
employed 3 mailings plus phone follow-up of non-
respondents. Of our mailed surveys to our sampled chir-
opractors (n = 5,931), we could verify that 2,598 surveys
actually reached a valid survey recipient (we deemed
3,333 of our initial list as “invalid” survey attempts, e.g.
invalid surveys were returned to us from US Postal Ser-
vice as “bad address”,o rw ec o n f i r m e dv i af o l l o w u pt h a t
surveys were not returned because the DC was retired or
deceased, therefore invalid). Of our valid survey contacts,
52% returned their surveys either partially or fully com-
pleted. Our overall mail survey response rate of 52% is
comparable to that of other surveys of busy professionals
[7-11]. We analyzed our survey data using SPSS for Win-
dows version 12.0 (SPSS Inc, Chicago, IL). This study
was reviewed and approved by the Palmer College Insti-
tutional Review Board.
Reported in this paper, from our 2,598 valid survey
contacts, we randomly selected 982 of these surveyed
chiropractors to receive a subset of survey questions
asking them whether they had ever identified a sus-
pected adverse drug event occurring in one of their
chiropractic patients, such as a prescription drug reac-
tion, interaction, or toxicity, and if so, how often this
had occurred during the prior two years. We also
prompted the chiropractors to describe recent examples
in narrative response, such as the chiropractic patient’s
main reason for seeking the chiropractor’s care, what
type of adverse drug event the chiropractor potentially
identified, what action the chiropractor took or recom-
mended, and the final outcome of the case. Of the 982
chiropractors that received the Adverse Rx Survey
Queries, 400 answered the questions, for an item-speci-
fic response rate of 41%.
Results
Of the 400 chiropractors that responded to our Adverse
Rx Survey questions, 62% report that they had identified
a suspected adverse drug event occurring in one of their
chiropractic patients. Over the course of a typical two-
year timeframe, half of those chiropractors reported hav-
ing identified 5 or less adverse drug events in their chir-
opractic patients, while the other half report identifying
upwards of 6 events over a two-year timeframe (see
Appendix 1).
Of those surveyed chiropractors who provided addi-
tional narrative responses about suspected adverse drug
events in their chiropractic patients (see Appendix 2),
some chiropractors mentioned specific drugs by name,
such as Lipitor (atorvastatin) or Zocor (simvastatin),
Celebrex (celecoxib), or Vicodin (hydrocodone). Adverse
drug events were also reported by chiropractors in rela-
tion to classes of drugs, such as antihypertensive drugs,
statins, or NSAIDs (Non-Steroidal Anti-Inflammatory
Drugs). The severity of suspected drug-related events
detected ranged from mild to severe. Appendix 3 and
Appendix 4 typify the narrative responses of chiroprac-
tors who offered examples of their experiences with
chiropractic patients who had apparent problems while
using statins or antihypertensive medications.
Discussion
Detection and Reporting
The US Food and Drug Administration (FDA) maintains
an internet-based “Medwatch” system for online report-
ing of adverse reactions and quality problems with
drugs, medical devices, other FDA-regulated products
such as dietary supplements, cosmetics, medical foods,
and infant formulas, or for reporting suspected counter-
feit medical products [12]. The user-friendly FDA Med-
watch system tracks adverse events reported by
consumers and healthcare providers, and adverse event
reports may be submitted by more than one reporter.
For instance, a single incident of a suspected adverse
drug event may be reported by the consumer, their
pharmacist, and their physician or other healthcare
provider.
Consumers who think that they or someone in their
family has experienced a serious reaction to a medical
product are encouraged to take the Medwatch reporting
form to their prescribing clinician, since that health care
provider can provide clinical information from the med-
ical record that can help FDA evaluate the suspected
adverse event report. The FDA 3500 Voluntary Adverse
Event Report Form can be downloaded directly from
the Medwatch website and faxed or mailed to FDA
Medwatch, or the adverse event report may be sub-
mitted to FDA via telephone (see Appendix 5). Med-
watch also advises consumers that health care providers
are not required to report to the FDA. If their health
care provider chooses not to fill out the FDA Voluntary
Adverse Event Report, or if the consumer does not wish
to have the form filled out by the health care provider,
or if the consumer wishes to also report the suspected
adverse event themselves, consumers may contact FDA
directly to report the adverse event (see Appendix 5).
Physicians and pharmacists are the healthcare provi-
ders who submit reports to FDA Medwatch most fre-
quently [13]. Other healthcare providers include nurses,
dentists and others. The MedWatch system is intended
to detect safety hazard signals for medical products, in
which case the FDA can issue medical product safety
alerts or order product recalls, withdrawals, or labeling
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information is disseminated to the medical community
and the general public via the MedWatch web site and
the MedWatch E-list. FDA Form 3500 should be used
by healthcare professionals for voluntary reporting of
adverse events noted spontaneously in the course of
clinical care, not events that occur during clinical trials
under an Investigational New Drug (IND) application.
The Form FDA 3500 Voluntary Adverse Event Report
Form should not be used to report suspected adverse
events involving vaccines, vaccine reports should be
submitted to the Vaccine Adverse Event Reporting Sys-
tem [14].
Healthcare providers are advised that the Health
Insurance Portability and Accountability Act (HIPAA)
Privacy Rule specifically permits covered entities (such
as hospitals, pharmacists, physicians and other clini-
cians) to report adverse events and other information
related to the quality, effectiveness and safety of FDA-
regulated products. This includes reports both to the
manufacturers and directly to FDA [15].
FDA Medwatch defines an adverse event as any unde-
sirable experience associated with the use of a medical
product in a patient. The event is serious and should be
reported when the patient outcome is death, life-threa-
tening, hospitalization (initial or prolonged), congenital
anomaly, disability, or the event resulted in a health
condition that required medical or surgical intervention
to preclude permanent impairment or damage to a
patient [16]. For FDA Medwatch reporting purposes,
disability is defined as a significant, persistent, or perma-
nent change, impairment, damage or disruption in the
patient’s body function/structure, physical activities or
quality of life. Medwatch advises healthcare providers
and consumers to report all suspected serious events,
even if they are not certain that the product caused the
event.
Serious or fatal adverse drug events reported to the
FDA (either directly through the MedWatch program or
to drug manufacturers) more than doubled from 1998
through 2005, with reported serious events increasing 4
times faster than the total number of outpatient pre-
scriptions during the period. Among the 15 drugs most
frequently named in fatal events, 7 were pain medica-
tions [17].
Clinical Case Management and Coordination of Care
Toward the development of evidence-based best prac-
tices for chiropractic clinical case management of sus-
pected adverse drug events in chiropractic patients, the
concept of a “triage” approach has been described as a
useful aid to the chiropractic clinician [18-20]. During
the differential workup of new chiropractic patients, or
for new complaints of established patients, triage
methods can help to foster safe, efficient, and effective
chiropractic patient management. For instance, “red
flagging” may identify emergent/urgent cases with signs
or symptoms that necessitate immediate or timely refer-
ral for medical care. Cautionary “yellow flagging” identi-
fies cases that warrant additional attention and followup,
and “green flagging” cases of limited concern.
Older adults are an especially vulnerable population of
chiropractic patients at risk of adverse drug events. As
noted in the USPHS Clinician’s Handbook of Preventive
Services (1
st ed, 1994): “Polypharmacy, the prescribing of
multiple drugs for a patient, is most common in older
adults because they tend to have more illnesses for
which medications are prescribed....Nonprescription
drug use among patients over age 65 years is seven
times that of the general population. The incidence of
adverse drug reactions increases with age and the num-
ber of drugs taken. Older adults make many mistakes in
taking medications due to deteriorating vision and cog-
nitive function, often with serious consequences....
changes in drug metabolism [also] occur with aging.
Renal and hepatic function decrease with age, thereby
slowing the clearance of medication. Increases in the
proportion of body fat and decreases in the proportion
of body water that occur with aging lead to an accumu-
lation of fat-soluble medications in adipose tissue and
increases in the concentration of hydrophilic medica-
tions in the blood.” As well, the older chiropractic
patient is at higher risk of falling due to medication use
and their higher likelihood of having concomitant pro-
blems with balance, gait, cognition, vision, strength, pos-
tural hypotension, painful arthritis, or depressive
symptoms [21-25].
While all elderly patients in the chiropractic practice
should be viewed as potential “yellow flag” cases at
greater risk of falls, those on medication and in particu-
lar frail elderly persons after hospital discharge, are
highly vulnerable to falls or other potential problems
such as adverse drug reactions, and warrant additional
cautionary attentiveness by the prudent clinician [26].
Adverse drug events have been implicated in ED use
a n dh o s p i t a l i z a t i o n st h a ta re potentially preventable
through better primary care management, particularly
for elder patients [27,28]. The medications most com-
monly involved in adverse reactions among patients
seen in the ED were insulins used to treat diabetes, pain
medications that contain opiates, and blood thinners.
Patients ages 65 and older who experienced adverse
reactions to medications were twice as likely to visit
EDs and seven times as likely to require hospitalization
as younger patients [29].
Younger individuals with a number of comorbidities,
or those taking pain medications, may represent
another inherently “yellow flag” cautionary population of
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Handbook of Preventive Services (1
st ed, 1994): “Poly-
pharmacy can occur in younger patients as well. As the
number of symptoms and diseases increases in an indi-
vidual, so does the risk of polypharmacy and the atten-
dant risk of overmedication and adverse effects.”
Preventable adverse drug events occurring in the
ambulatory setting may directly result in serious perma-
nent injury or death [28]. However, even indirect
adverse outcomes of drug reactions are important, in
that drug reactions such as fatigue, dizziness, or pro-
blems with balance may predispose individuals to higher
risk of fall, motor vehicle accident, occupational hazard,
or other serious indirect consequences [30]. Recently
estimated, as many as one fourth to one third of
patients may experience an adverse reaction to a medi-
cation prescribed in primary care or ambulatory settings
[30-32]. Medication reaction symptoms frequently
reported include the aforementioned as well as rash,
itching, and gastrointestinal problems, and medications
that have been typically implicated by patients reporting
adverse reactions include oral corticosteroids, nonnarco-
tic analgesics, and nonsteroidal anti-inflammatory agents
(NSAIDS) any of which may be prescribed for back pain
[30,31]. Many drug-attributed symptoms occur with
every dose and persist for a month or longer, cause
patients discomfort and worry, cause patients to seek
additional medical attention, compromise patient adher-
ence to prescribed drug regimens, and lower overall
patient satisfaction [30-32].
Drug-related mental health effects are a serious con-
cern. For instance, patients undergoing prolonged corti-
costeroid therapy for inflammatory musculoskeletal or
other chronic conditions are at risk for developing
symptoms of corticosteroid-induced psychosis [33-37].
Psychiatric symptoms may develop at any time during
the course of corticosteroid therapy, or even after cessa-
tion of therapy, and may manifest as memory deficits,
manic or depressive symptoms, or frank psychosis.
Chiropractic patients using statins may also warrant
“yellow flagging”. Potential consumer safety issues
related to statin use have been identified repeatedly by
FDA Medwatch [38-41]. In addition to the FDA warn-
ings about the risk of severe statin-related musculoskele-
tal affects such as rhabdomyolysis, increasing scientific
and clinical attention is being directed toward determin-
ing the potential risk for statin-associated tendinous dis-
orders (tendinitis and tendon rupture), and to alerting
clinicians that early recognition of such tendinous com-
plications related to statins may be important in pre-
venting serious sequelae in patients being treated with
statins [42-44].
Collaborative care is a recognized standard of chiro-
practic professional practice, and has been defined in
chiropractic standards of care as “the reciprocal inter-
professional interaction between health care providers in
the management of the patient... including basic famil-
iarity with the procedures and terminology of other clin-
ical disciplines... and appropriate and timely referral as
needed... including exchange of pertinent information”
[45]. Nonprescribing chiropractic clinicians in the US
may be customarily taught that “no advice regarding
taking or withdrawing from, or increasing or decreasing
dosages can be given without violating state scope of
practice laws...however when a problem [with medica-
tions] is suspected or recognized, it is imperative that
the chiropractor either send the patient back to the pre-
scribing [clinician] with informative questions or contact
the prescribing [clinician] to discuss the individual
patient’ [46]. The legal parameters governing chiroprac-
tic professional standards of care are largely defined by
state rule making authority through administrative
boards or direct legislative action (i.e. state scope-of-
practice laws), by consensus-based practice guidelines,
or by training curricula [47]. However, it is less clear
what are the parameters governing cross-disciplinary
collaborative care of patients shared between prescribing
clinicians and nonprescribing clinicians such as chiro-
practors. For instance, chiropractors without prescriptive
authority may perceive that reporting or referring sus-
pected adverse drug events may place them on ques-
tionable grounds in terms of HIPAA, or their scope of
practice, or their potential shared exposure to malprac-
tice liability [48]. It is unknown to what extent chiro-
practors feel that their pregraduate chiropractic training
or postgraduate continuing education adequately pre-
pares them to understand the fundamental mechanisms
of pharmacology or toxicology, much less how best to
apply that understanding toward appropriate detection
of suspect cases of adverse drug effects.
Fragmentation and lack of coordination between pro-
viders compromises patient safety and undermines qual-
i t yo fc a r ea n dt h ee f f i c i e n c yo ft h eh e a l t hc a r ed e l i v e r y
system [49-52]. Relying on patients to contact other
physicians on their own breaks continuity of care
[53,54]. Many patients may not report medication-
related symptoms to their prescribing clinicians, or pre-
scribing clinicians may not solicit such concerns from
the patient nor address those concerns if raised by the
patient [55]. Adverse drug events due to patient nonad-
herence to prescribed drug regimens are potentially pre-
ventable by timely identification and notification to
prescribing clinicians [56]. Some adverse drug events in
primary care, such as medication errors or potential
problems with acute medication prescriptions such as
narcotics, may also be prevented or averted by pharma-
cists in the community [57]. Timely detection of adverse
drug events is imperative, particularly since certain drug
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disabling, such as ototoxic loss of hearing or balance
[58,59].
In addition to medication intolerance, individual
patients may have other reasons for nonadherence, or
for being averse to taking prescription medicines them-
selves or averse to allowing their children to take drugs.
For instance individuals or families may have a history
of substance abuse, or a suspected familial or genetic
predisposition to potential problems with chemical
dependency or medication intolerance. In 2006, there
were 10.2 million persons aged 12 or older who
reported driving under the influence of illicit drugs, and
the illicit use category with the largest number of recent
initiates to substance use among persons aged 12 or
older was the nonmedical use of pain relievers. Among
persons aged 12 or older who used pain relievers non-
medically, over half reported that the source of the drug
was from a friend or relative for free, and 80% of the
time that friend or relative had obtained the drugs from
just one doctor [60]. Or individuals may simply prefer
not to take drugs, and seek out alternative or comple-
mentary non-pharmacologic options for their health
care needs. There is a potential role for nonprescribing
clinicians such as chiropractors to identify instances of
suspected adverse drug reactions or medication intoler-
ance, nonadherence, medication errors, or other pro-
blems with prescribed drug regimens.
Conclusion
Adverse drug events are a major problem and are often
undetected. We surveyed US chiropractors about their
actual or potential role in advancing patient safety initia-
tives to monitor adverse drug events. Our findings sug-
gest that chiropractors or other nonprescribing
clinicians may be in a position to detect potential
adverse drug events in the community. These detection
and reporting mechanisms should be standardized and
policies related to clinical case management of suspected
adverse drug events occurring in chiropractic patients
should be developed.
We recommend advancing a multidisciplinary consen-
sus-based approach to improving the integration and
coordination of care for patients with suspected adverse
drug reactions in the community. Prescribing clinicians,
nonprescribing clinicians, and informed others such as
pharmacists, should jointly develop and disseminate
appropriate standards for intra-disciplinary and inter-
disciplinary clinical case management of suspected
adverse drug reactions in their shared patients. Optimal
collaborative care should include appropriate documen-
tation and communication of useful information, timely
notification, and diligent follow-up. More research is
needed to better understand the extent, or variation, of
chiropractor knowledge, attitudes, and behaviors,
regarding their actual and potential roles in screening
their patients for potential adverse drug events. More
scholarly attention is warranted to further inform expert
consensus about what constitutes a useful and necessary
skillset (and requisite preparatory training) of nonpre-
scribing clinicians to detect adverse drug events, and to
ensure that suspect cases are brought to the attention
of the prescribing clinician in a timely and useful
manner.
Appendix 1: Frequency of chiropractors who
identified suspected adverse drug events in their
chiropractic patients
Did chiropractor ever identify a suspected adverse
drug event in one of their chiropractic patients, such
as prescription drug reaction, interaction, or toxicity?
Yes 62%
If Yes, How often did chiropractor identify sus-
pected adverse drug events within the past 2 years?
5 times or less 48%
6-10 times 19%
11-20 times 15%
21-40 times 10%
>40 times 8%
Appendix 2: Chiropractors described suspected
adverse drug events in their chiropractic patients
by Rx drug name, Rx drug type, or other
unspecific mention
■ Suspected adverse drug events in chiropractic
patients with specific mention of the Rx drug
name ( e . g .L i p i t o r ,Z o c o r ,B a y c o l ;C e l e b r e x ,V i o x x ;
Prozac, Xanax, Paxil, Wellbutrin, Vicodin, Oxyco-
done, Percocet, Haldol, Glucophage, Fosomax)
■ Rx mentioned by drug type (e.g. hypertension
meds, blood pressure meds; statins, cholesterol
meds; pain meds, narcotics, muscle relaxors, corti-
costeroids, NSAIDS, anti-inflammatories, predni-
sone, antidepressants, asthma meds, seizure meds,
heart/cardiac meds, coumadin)
■ Other (e.g. Over-the-Counter (OTC) specifically
mentioned by name or type such as NSAIDS, anti-
inflammatories, or pain meds; Reactions to Vac-
cines; Nondescript reference to “meds"; or Vitamins
or herbs).
Appendix 3: Example of narrative responses from
chiropractors describing suspected adverse drug
events in their chiropractic patients using statins
■ “[chiropractic] patient with multiple severe muscle
aches and cramps: resolved within days of
removal from zocor/lipitor/baycol, etc“
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on lipitor“
■ “many patients [in chiropractor’sp r a c t i c e ]p r e -
scribed lipitor med which caused muscle weakness
as side effect“
■ “several cases [in chiropractor’s practice] of choles-
terol medication causing systemic pains, [chiro-
practor] referred cases back to MD who modified
meds“
■ “several people [in chiropractor’sp r a c t i c e ]o n
anticholesterol drugs - when off the drugs did
much better overall”
Appendix 4: Example of narrative responses from
chiropractors describing suspected adverse drug
events in their chiropractic patients using
antihypertensive drugs
■ “[chiropractic patient] with fatigue and chest pain
[apparent] reaction to new [blood pressure] medi-
cation - [chiropractor] referred patient back to
prescribing MD...MD changed medication, pro-
blem resolved“
■ “...[chiropractic patient] with low blood pressure...
fainted in my chiropractic office...[patient] was
taking high blood pressure med...MD revised
patient’s medication...”
■ “[chiropractic patient] with dizziness, side effect of
hypertension med...[chiropractor] recommended
patient to consult their primary care provider,
MD discontinued med... “
■ “many patients [in chiropractor’s practice] having
problems with blood pressure meds (too much
and too little) - chiropractor referred patients
back to MD to alter dose“
■ “[chiropractic patient] with vertigo, patient on
blood pressure Rx... chiropractor referred to pre-
scribing physician for evaluation, changed Rx “
■ “chiropractic patient involved in motor vehicle
accident, headaches...diagnosed by chiropractor
essential hypertension...chiropractor referred
patient to primary care for evaluation...patient
returned to chiropractor for further care, had
adverse reaction to blood pressure meds... chiro-
practor referred patient back to primary care for
re-evaluation [blood pressure med]“
■ “[chiropractic] patient with dizziness, taking blood
pressure meds...chiropractor sent patient back to
cardiologist for meds“
Appendix 5: Instructions for Consumer reporting
to FDA MedWatch
Reporting to FDA Medwatch System can be conducted
online http://www.fda.gov/Safety/MedWatch/default.htm,
by phone 1-800-FDA-1088, or by submitting the
MedWatch 3500 form by mail (MedWatch 5600 Fishers
Lane, Rockville, MD°20852-9787) or fax 1-800-FDA-0178.
The FDA Form 3500 is available for download from
FDA Medwatch webpage: http://www.fda.gov/down-
loads/Safety/MedWatch/HowToReport/Download-
Forms/UCM082725.pdf.
Instructions for consumer reporting downloaded on
May 13, 2010, from FDA Medwatch webpage: http://
www.fda.gov/Safety/MedWatch/HowToReport/
ucm053074.htm.
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